LambdaVision
LambdaVision is a pre-clinical biotechnology company developing the first protein-based artificial retina, manufactured in microgravity aboard the International Space Station via a patented layer-by-layer bacteriorhodopsin process, to restore vision in patients with retinitis pigmentosa and age-related macular degeneration.
- Company typePrivate
- Founded2009
- HeadquartersFarmington, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What LambdaVision does
LambdaVision is a privately held, pre-clinical-stage biotechnology company founded in 2009 at the UConn Technology Incubator Program that is developing the first protein-based artificial retina to restore meaningful vision in patients blinded by advanced retinal degenerative diseases, principally retinitis pigmentosa (RP) and, subsequently, age-related macular degeneration (AMD). The company's core technology is a layer-by-layer (LbL) thin-film process that alternates the light-activated protein bacteriorhodopsin with a polymer on a synthetic-fiber membrane to build a 200-layer implant that absorbs incident light and stimulates remaining retinal neural circuitry without requiring external power, electrodes, or bulky hardware. The process is patent-protected (USPTO worldwide patent US20200054441A1) and has been validated across nine missions to the International Space Station in partnership with Space Tango using automated CubeLab hardware, where microgravity conditions deliver superior layer uniformity, optical clarity, and material efficiency versus Earth-based production. The company is led by CEO Nicole L. Wagner, PhD (a UConn co-founder of the technology), CSO Jordan A. Greco, PhD, and founder Dr. Robert R. Birge, with a board that includes seasoned biotech operators and the Connecticut Innovations investor.
LambdaVision has no commercial product and is pre-revenue. Current revenue mechanics consist entirely of non-dilutive grant funding from NASA (SBIR Phase II, InSPA Phase 2, $5M Commercialization Award), the National Science Foundation, the National Eye Institute/NIH, and the Connecticut Bioscience Innovation Fund (~$12M cumulatively from NASA/ISS National Lab), supplemented by priced equity rounds including a 2018 Series A from Connecticut Innovations, a 2024 first seed closing led by Aurelia Foundry Fund, and a $7M seed round in November 2025 co-led by Seven Seven Six and Aurelia Foundry Fund with Seraphim Space, providing stated runway into 2027. Total funding raised to date is approximately $22-23M. Future revenue is expected to come from one-time hardware sales of the artificial retina implant to retinal specialists and academic medical centers (e.g., Yale School of Medicine with Dr. Luciano V. Del Priore as an early clinical champion), with longer-term optionality from licensing the underlying LbL protein film platform for adjacent applications in biosensors, optical systems, tissue engineering, and drug delivery.
The go-to-market motion is a hybrid of strategic co-development partnerships (Space Tango, Helogen, Starlab/Voyager, Vast) for orbital manufacturing and future direct-to-clinical-site field sales for the implant itself, supported by PR/earned media, content marketing, conference presence, and event-driven investor cultivation (CEO speaking at Payload Investors Summit November 2025). To secure post-ISS manufacturing redundancy ahead of the 2030 ISS retirement, the company has pre-booked payload slots on three independent commercial space infrastructure platforms — Starlab Space, Vast's Haven-1 and successors, and Helogen's HEL-IOS — while continuing IND-enabling preclinical studies targeted at advanced retinitis pigmentosa as the first clinical indication and age-related macular degeneration as the second.
LambdaVision firmographics
Firmographics- Name
- LambdaVision
- Legal name
- LambdaVision, Inc.
- Website
- https://lambdavision.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- LambdaVision is a pre-clinical biotechnology company developing the first protein-based artificial retina, manufactured in microgravity aboard the International Space Station via a patented layer-by-layer bacteriorhodopsin process, to restore vision in patients with retinitis pigmentosa and age-related macular degeneration.
- Ownership category
- akta.pro rank
LambdaVision industry classification
Industry- Product category
- Ophthalmology Medical Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades) (HLAHAJAJ)
- akta.pro secondary industry
- Retina & Vitreous Specialists (HLAKAKAE)
Keywords
Where LambdaVision is headquartered
LocationHeadquarters
- HQ city
- Farmington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
LambdaVision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Non-dilutive government and foundation grants: Pre-clinical funding sourced from NASA (SBIR Phase II, InSPA commercialization awards, ~$12M from NASA and ISS National Lab), the National Science Foundation, and the National Eye Institute/NIH; these funds support preclinical studies, scale-up, and ISS mission costs.
- Equity (venture capital) financing: Pre-revenue company; capital is raised through priced equity rounds (notably a $7M seed round co-led by Seven Seven Six and Aurelia Foundry Fund in November 2025, and an earlier Series A from Connecticut Innovations in 2018) used to fund operations through IND-enabling studies and a planned future Series A.
- Future product sales of protein-based artificial retina implant: Planned future commercial revenue from sale of the protein-based artificial retina as a one-time implant to treat advanced retinitis pigmentosa and later age-related macular degeneration, following regulatory clearance and clinical trials.
- Future platform licensing for adjacent applications: Longer-term licensing/royalty potential from the LbL protein film platform for biosensors, optical systems, tissue engineering, and drug delivery applications once the core artificial retina is commercialized.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels5 records
LambdaVision product offering
Product offeringCore offering
LambdaVision develops an investigational protein-based artificial retina implant produced by layer-by-layer deposition of approximately 200 thin films of the light-activated protein bacteriorhodopsin alternating with a polymer on a synthetic-fiber membrane. Manufacturing is conducted in microgravity aboard the International Space Station using Space Tango CubeLab hardware to achieve superior layer uniformity, optical clarity, and material efficiency, with the implant designed to restore meaningful vision in patients blinded by advanced retinitis pigmentosa and age-related macular degeneration.
Differentiator
Problem solved
Functional benefit
Products and services
- Protein-Based Artificial Retina (investigational implant for retinitis pigmentosa and AMD)
Quantifiable outcome
- 9 of 9 ISS missions successfully produced multiple 200-layer protein thin films in microgravity
- +4 more outcomes
Companies that use LambdaVision
Customer profileSegments3 records
Ideal customer profiles4 records
LambdaVision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
LambdaVision partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered strategic (post-iss mou), flagship (first mission outside the iss), flagship (post-iss commercial manufacturing anchor), flagship (starlab lead; nyse: voyg), flagship (long-running implementation partner), flagship (multi-program government partner) and strategic (clinical advisor).
- Vaststrategic (post-iss mou)Signed a memorandum of understanding on June 24, 2026 with Vast to continue and expand LambdaVision's biomedical research on Vast's Haven-1 and future commercial space stations, after the ISS is retired at the end of the decade. Vast's partner network also includes the Sanford Stem Cell Institute at UC San Diego, Auxilium Biotechnologies, and BioOrbit.
- Helogen Corporationflagship (first mission outside the iss)Strategic partnership announced May 18, 2026 to launch LambdaVision's first orbital manufacturing mission outside the ISS aboard Helogen's fully autonomous HEL-IOS™ manufacturing system in low-Earth orbit, targeted for the second half of 2026. Validates the full operational chain for GMP-compliant production of the artificial retina in LEO, including ground preparation, flight qualification, in-orbit manufacturing, sample return, and custody transfer. Connection initiated through the 2023 Boryung Humans in Space challenge. Helogen also won the 2025 NASA TechLeap Prize.
- Starlab Space LLCflagship (post-iss commercial manufacturing anchor)Reservation agreement signed February 24, 2026 for payload slots and commercial space on Starlab's next-generation commercial space station. Supports LambdaVision's transition from research demonstration to scalable, sustainable manufacturing in low-Earth orbit ahead of the 2030 ISS retirement. Starlab is a U.S.-led global JV among Voyager Technologies, Airbus, Mitsubishi Corporation, MDA Space, Palantir Technologies, and Space Applications Services, with strategic partners Hilton, Journey, Northrop Grumman, and The Ohio State University.
- Voyager Technologiesflagship (starlab lead; nyse: voyg)Lead joint-venture partner in Starlab Space; partnered with LambdaVision through the Starlab payload reservation announced February 24, 2026 to provide commercial space station access in low-Earth orbit. Seraphim Space is an investor in both LambdaVision and Voyager, enabling portfolio collaboration.
- Space Tangoflagship (long-running implementation partner)Long-term implementation partner for LambdaVision's ISS missions; provides automated CubeLab hardware on the ISS U.S. National Laboratory. The partnership has secured >$7.7M in funding from NASA and supported all 9 of LambdaVision's ISS investigations refining the LbL manufacturing process. Space Tango is headquartered in Lexington, KY.
- NASAflagship (multi-program government partner)Long-standing funding and program partner: NASA SBIR Phase II awards, InSPA commercialization awards, the September 2025 Phase 2 InSPA award, and access to the ISS U.S. National Laboratory have collectively provided roughly $12M in non-dilutive funding and 9 ISS missions. NASA's programs underpin LambdaVision's IND-enabling and GMP manufacturing scale-up.
- Yale School of Medicine (Ophthalmology)strategic (clinical advisor)Clinical research collaboration with Dr. Luciano V. Del Priore, MD, PhD — Robert R. Young Professor of Ophthalmology and Visual Science, Chair of Ophthalmology at Yale School of Medicine, and Chief of Ophthalmology at Yale New Haven Hospital — supporting the artificial retina's preclinical and clinical translation.
Scale indicators9 records
Recent moves9 records
Expansion highlights6 records
LambdaVision competitors and assessment
Company assessmentDirect peers
- Pixium Vision: Pixium Vision developed the PRIMA photovoltaic sub-retinal prosthesis for advanced dry AMD, gaining EU/UK CE marking. It is the most direct retinal implant competitor to LambdaVision, using a different (electronic photovoltaic) mechanism but targeting the same RP/AMD patient population with a surgically implanted retinal prosthesis.
- Second Sight Medical Products (now Nano Precision Medical): Second Sight developed and commercialized the Argus II epiretinal prosthesis, the first FDA-approved retinal implant for RP. After discontinuing the Argus business, the company refocused as Nano Precision Medical with a drug delivery platform. Argus II is the historical benchmark for retinal prosthesis regulatory and commercial pathways that LambdaVision will be compared against.
- Bionic Vision Technologies: Bionic Vision Technologies is an Australian company developing a suprachoroidal retinal prosthesis for patients with retinitis pigmentosa. It is a direct peer because it is pursuing a retinal implant for the same RP indication with a similar surgical implantation approach, though using electrode-based rather than protein-based stimulation.
Emerging players
- jCyte: jCyte is developing a stem cell-based therapy (jCell) for retinitis pigmentosa aimed at preserving and restoring vision through paracrine effects on remaining photoreceptors. It is an emerging peer because it targets the same RP patient population via an alternative mechanism (cell therapy rather than prosthesis) and represents potential competitive pressure on LambdaVision's lead indication.
- ProQR Therapeutics: ProQR Therapeutics develops RNA-editing therapies (AOC platform) for inherited retinal diseases including RP and Leber congenital amaurosis. It is an emerging peer because its genotype-specific approach competes for portions of the RP market that LambdaVision's genotype-agnostic protein implant would otherwise address.
- SparingVision: SparingVision is a French clinical-stage biotech developing gene therapies (SPVN06, SPVN20) targeting RP and dry AMD. It is an emerging peer because it is pursuing mutation-agnostic gene therapy approaches for RP that overlap directly with LambdaVision's lead indication and could reach patients before a protein-based implant is approved.
- GenSight Biologics: GenSight Biologics develops gene therapies for retinal and CNS disorders, with Lumevoq approved in EU/UK for Leber hereditary optic neuropathy (LHON) and GS030 in development for RP. It is an emerging peer in the broader retinal-disease treatment space where LambdaVision's protein implant would compete.
Others
- Varda Space Industries: Varda Space Industries is building in-space pharmaceutical manufacturing and reentry capability, having successfully returned the first space-manufactured drug product. It is an "others" peer because it operates the same low-Earth-orbit biomanufacturing thesis as LambdaVision but in small-molecule formulation rather than protein-based therapeutics, signaling the broader commercial validation of orbital drug production.
Broad incumbents
- Regeneron Pharmaceuticals: Regeneron commercializes Eylea (aflibercept) and Eylea HD, the leading anti-VEGF therapies for wet AMD and other retinal diseases. It is a broad incumbent because, while not pursuing a restorative implant, it dominates the standard-of-care market that LambdaVision's protein implant would either complement or partially substitute in the AMD patient population.
- Roche (Genentech): Roche/Genentech markets Lucentis (ranibizumab) and Vabysmo (faricimab), the leading anti-VEGF therapies for wet AMD and related retinal conditions. It is a broad incumbent that defines the current treatment paradigm for the AMD market LambdaVision aims to enter with a restorative implant for advanced disease.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
LambdaVision social profiles
Digital presenceLambdaVision financial estimates
Financial estimateRevenue estimate
Valuation estimate
LambdaVision leadership team
Management profileNumber of profiles
Profiles7 records
LambdaVision funding detail
Funding detailFunding overview
Funding rounds9 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LambdaVision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LambdaVision
What does LambdaVision do?
LambdaVision develops an investigational protein-based artificial retina implant produced by layer-by-layer deposition of approximately 200 thin films of the light-activated protein bacteriorhodopsin alternating with a polymer on a synthetic-fiber membrane. Manufacturing is conducted in microgravity aboard the International Space Station using Space Tango CubeLab hardware to achieve superior layer uniformity, optical clarity, and material efficiency, with the implant designed to restore meaningful vision in patients blinded by advanced retinitis pigmentosa and age-related macular degeneration.
Is LambdaVision a public or private company?
LambdaVision is a private company. It is classified as venture growth investor backed and is currently operating.
When was LambdaVision founded?
LambdaVision was founded in 2009. It employs 1 to 10 people.
Where is LambdaVision based?
LambdaVision is headquartered in Farmington, United States, in the North America region.
How does LambdaVision make money?
Four revenue lines are on record. Non-dilutive government and foundation grants are the primary driver. The others are equity (venture capital) financing, future product sales of protein-based artificial retina implant and future platform licensing for adjacent applications.
Who are LambdaVision's main competitors?
Direct peers on record are Pixium Vision, Second Sight Medical Products (now Nano Precision Medical) and Bionic Vision Technologies. Emerging players are jCyte, ProQR Therapeutics, SparingVision and GenSight Biologics. Varda Space Industries is listed as an others. Broad incumbents are Regeneron Pharmaceuticals and Roche (Genentech).
Does LambdaVision have an API?
No public API is recorded for LambdaVision.
What industry is LambdaVision in?
LambdaVision's product category is Ophthalmology Medical Devices. Its primary akta.pro industry code is HLAHAJAJ, Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades), with a secondary code of HLAKAKAE, Retina & Vitreous Specialists. Its NAICS code is 339115 and its SIC code is 3851.